Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week 2026

AI-generated NewsSnap summary based on source reporting.
Published: 2026-10-18
Category: business
Source: Markets Insider

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company, announced it will present clinical data across all three of its IBD antibodies, including SPY001, at United European Gastroenterology Week (UEGW) 2026 in Barcelona. This marks the first scientific congress presentation of this clinical data.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai